Intraperitoneal immunotherapy for metastatic ovarian carcinoma: Resistance of intratumoral collagen to antibody penetration

Clinical Cancer Research

Volumn 12, Issue 6, 2006, Pages 1906-1912

  Choi, Jaehwa ^a   Credit, Kimberly ^a   Henderson, Karla ^a   Deverkadra, Ravi ^a   He, Zhi ^a   Wiig, Helge ^b   Vanpelt, Heather ^a   Flessner, Michael F ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COLLAGENASE; HYALURONIC ACID; HYALURONIDASE; IMMUNOGLOBULIN G ANTIBODY; TRASTUZUMAB;

ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DISTRIBUTION VOLUME; EXTRACELLULAR MATRIX; FEMALE; IMMUNOTHERAPY; ISOTOPE LABELING; METASTASIS; NONHUMAN; OVARY CARCINOMA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; SEROSA; TISSUE PRESSURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; COLLAGEN; COLLAGENASES; EXTRACELLULAR MATRIX; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN G; IMMUNOTHERAPY; INJECTIONS, INTRAPERITONEAL; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645693408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2141     Document Type: Article

References (45)

1. Markman M. Intraperitoneal therapy of ovarian carcinoma. Semin Oncol 1998;25:356-60.
2. Gershenson DM, Tortolero-Luna G, Malpica A, et al. Ovarian intraepithelial neoplasia and ovarian cancer. Obstet Gynecol Clin North Am 1996;23:475-543.
3. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol 2005;97:10-5.
4. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
5. Barakat RR, Sabbatini P, Bhaskaran D, et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. J Clin Oncol 2002;20:694-8.
6. Quadri SM, Malik AB, Tang XZ, et al. Preclinical analysis of intraperitoneal administration of In-111-labeled human tumor reactive monoclonal IgM AC6C3-2B12. Cancer Res 1995;55:5736-42s.
7. Alvarez RD, Partridge EE, Khazaeli MB, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997;65:94-101.
8. Kairemo KJ. Radioimmunotherapy of solid cancer: a review. Acta Oncol 1996;35:343-55.
9. Kievit E, Pinedo HM, Schluper HM, Boven E. Addition of cisplatin improves efficiency of I-131-labelled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 2004;38:419-28.
10. See HT, Kavanagh JJ. Novel agents in epithelial ovarian cancer. Cancer Invest 2004;2:29-44.
11. Wiig H, Kaysen GA, Al-Bander HA, et al. Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. Am J Physiol 1994;266:H212-9.
12. Dedrick RL, Flessner MF. Pharmacokinetic considerations on monoclonal antibodies. Cancer Immun 1989;11:429-38.
13. Flessner MF, Dedrick RL. Monoclonal antibody delivery to intraperitoneal tumors in rats: effects of route of administration and intraperitoneal solution osmolality. Cancer Res 1994;54:4376-84.
14. Flessner MF, Choi J, He Z, Credit K. Physiological characterization of human ovarian cancer cells in a rat model of intraperitoneal antineoplastic therapy. J Appl Physiol 2004;97:1518-26.
15. Flessner MF, Choi J, Credit K, et al. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 2005;11:3117-25.
16. Gyenge C, Tenstad O, Wiig H. In vivo determination of steric and electrostatic exclusion of albumin in rat skin and skeletal muscle. J Physiol 2003;552:907-16.
17. Flessner MF, Lofthouse J, Zakaria ER. In vivo diffusion of immunoglobulin G in muscle: effects of binding, solute exclusion, and lymphatic removal. Am J Physiol 1997;273:H2783-93.
18. Wiig H, Aukland K, Tenstad O. Isolation of interstitial fluid from rat mammary tumors by a centrifugation method. Am J Physiol Heart Circ Physiol 2003;284: H416-24.
19. Wiig H, DeCarlo M, Sibley L, Renkin EM. Interstitial exclusion of albumin in rat tissues measured by a continuous infusion method. Am J Physiol 1992;263: H1222-33.
20. Wiig H, Reed RK, Aukland K. Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to the wick-in-needle technique. Microvasc Res 1981;21:308-19.
21. Flessner MF. Small-solute transport across specific peritoneal tissue surfaces in the rat. J Am Soc Nephrol 1996;7:225-33.
22. Flessner MF, Lofthouse J. Hyaluronan content controls convective movement of protein and water through the subperitoneal interstitium. J Am Soc Nephrol 2000;11:207.
23. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-503.
24. Flessner MF, Fenstermacher JD, Blasberg RG, Dedrick RL. Peritoneal absorption of macromolecules studied by quantitative autoradiography. Am J Physiol 1985;248:H26-32.
25. Lokeshwar VB, Rubinowicz D, Schroeder GL. Stromal and epithelial expression of tumor markers hyaluronan and HYAL1 hyaluronidase in prostate cancer. J Biol Chem 2001;276:11922-32.
26. Tammi R, MacCallum D, Hascall VC, et al. Hyaluronan bound to CD44 on keratinocytes is displaced by hyaluronan decasaccharides and not hexasaccharides. J Biol Chem 1998;273:28878-88.
27. Reddy G, Enwemeka C. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996;29:225-9.
28. Flessner MF, Dedrick RL, Reynolds JC. Bidirectional peritoneal transport of immunoglobulin in rats: tissue concentration profiles. Am J Physiol 1992;263: F15-23.
29. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1.
30. Yen MS, Juang CM, Lai CR, et al. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int J Gynaecol Obstet 2001;72:55-60.
31. Fujiwara K, Sakuragi N, Suzuki S, et al. First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up. Gynecol Oncol 2003;90:637-43.
32. Tournigand C. Intraperitoneal chemotherapy in ovarian cancer: who and when? Curr Opin Obstet Gynecol 2005;17:83-6.
33. Flessner MF, Dedrick RL, Reynolds JC. Bidirectional peritoneal transport of immunoglobulin in rats: compartmental kinetics. Am J Physiol 1992;262:F275-87.
34. Flessner MF. Transport of water-soluble solutes between the peritoneal cavity and plasma in the rat. Ann Arbor (Michigan): University of Michigan; 1981.
35. Laurent TC. Structure of the extracellular matrix and the biology of hyaluronan. In: Reed RK, McHale NG, Bert JL, et al., editors, Interstitium, connective tissue, and lymphatics. 1st ed. London: Portland Press; 1995. p. 1-12.
36. Freedman RS, Deavers M, Liu JWE. Peritoneal inflammation-a microenvironment for epithelial ovarian cancer (EOC). J Transl Med 2004;2:23.
37. Wiig H, Tenstad O. Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am J Physiol Heart Circ Physiol 2001;280:H1505-12.
38. Wiig H, Gyenge CC, Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005;567:557-67.
39. Fraser JRE, Laurent TC. Hyaluronan. In: Comper WD, editor. Extracellular matrix, vol. 2 ed. Amsterdam: Harwood Academic Publishers; 1996. p. 141-99.
40. Scott JE, Heatley F. Hyaluronan forms specific stable tertiary structures in aqueous solution: a C-13 NMR study. Proc Natl Acad Sci U S A 1999;96:4850-5.
41. Gribbon P, Heng BC, Hardingham TE. The molecular basis of the solution properties of hyaluronan investigated by confocal fluorescence recovery after photobleaching. Biophys J 1999;77:2210-6.
42. Brekken C, Hjelstuen MH, Bruland OS, deLange-Davies C. Hyaluronidase-induced periodic modulation of the interstitial fluid pressure increases selective antibody uptake in human ostesarcoma xenografts. Anticancer Res 2000;20:3513-9.
43. deLange-Davies C, Engesaeter BO, Haug I, et al. Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituents. Br J Cancer 2001;85:1968-77.
44. Eikenes L, Bruland OS, Brekken C, deLange-Davies C. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res 2004;64:4768-73.
45. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961;93:440-7.